Miriam E. Tucker

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean mass and promote fat mass loss.

Tirzepatide reduced weight, A1c, and insulin dose in type 1 diabetes in a small randomized controlled trial.

In its first evidence-based clinical practice guidelines, the European Association for the Study of Diabetes advises clinicians to inquire about the emotional aspects of diabetes.

The European Association for the Study of Diabetes has called for universal autoantibody screening for early-stage type 1 diabetes in children beginning at age 2.

At least two retrospective observational studies now suggest that tirzepatide safely reduces weight, A1c, and insulin requirements in type 1 diabetes, with randomized control trial data to come.

The upcoming meeting of the European Association for the Study of Diabetes will feature results from clinical trials in types 1 and 2 diabetes and obesity and new clinical practice guidelines.

FDA Establishes ‘Green List’ to Protect US GLP-1 Supply

Diabetes Tech Access Linked to A1c in Kids With T1D Globally

The FDA also cleared the SmartGuard algorithm enabling integration with the Instinct, a new sensor made by Abbott.

The Signos platform combines a continuous glucose monitor with an artificial intelligence-based app to guide users regarding food and movement.